Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00446095 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
A Phase 1 study, sponsored by Rigel Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT00446095 is a Phase 1 study that has completed, run by Rigel Pharmaceuticals. The registered enrollment target is 81 participants.
The verdict
NCT00446095, a Phase 1 study, has completed, sponsored by Rigel Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
Patients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16 patients (nodular, diffuse large cell, mantle cell plus others). Oral bid dosing with highest tolerable dose until toxicity, progression, or withdrawal
Interventions
- DRUG fostamatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00446095
The ClinicalTrials.gov registry entry for NCT00446095 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rigel Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fostamatinib is the first listed.
NCT00446095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00446095 about?
NCT00446095 is a clinical study titled "Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma". Patients: B-cell lymphoma, refractory, diffuse, nodular, mantle, other Phase I : Two groups of 6 patients, escalating dose tolerability- 28 days Phase II: Three groups of 16 patients (nodular, diffuse large cell, mantle cell plus others). Oral bid dosing with highest tolerable dose until toxicity, p...
What is the current status of trial NCT00446095?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2007-04. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00446095?
The interventions under investigation include: fostamatinib (DRUG).
Who is sponsoring clinical trial NCT00446095?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.